Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort study

@inproceedings{Yuan2018RiskOL,
  title={Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort study},
  author={Zhong Yuan and Frank J. DeFalco and Patrick B. Ryan and Martijn J. Schuemie and Paul E. Stang and Jesse A Berlin and Mehul Desai and Norm Rosenthal},
  booktitle={Diabetes, obesity & metabolism},
  year={2018}
}
AIMS To examine the incidence of amputation in patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose co-transporter 2 (SGLT2) inhibitors overall, and canagliflozin specifically, compared with non-SGLT2 inhibitor antihyperglycaemic agents (AHAs). MATERIALS AND METHODS Patients with T2DM newly exposed to SGLT2 inhibitors or non-SGLT2 inhibitor AHAs were identified using the Truven MarketScan database. The incidence of below-knee lower extremity (BKLE) amputation was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 42 times over the past 90 days. VIEW TWEETS
3 Extracted Citations
23 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 23 references

and Drug Administration

  • US Foo
  • FDA confirms increased risk of leg and foot…
  • 2017
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…